Rep. Gilbert Cisneros (D-CA) Buys ARQT Stock

Representative Gilbert Cisneros, a Democrat representing California's 31st district in the U.S. House, recently disclosed a purchase of Arcutis Biotherapeutics, Inc. (ARQT) stock. According to a periodic transaction report filed under the STOCK Act, the trade took place on May 29, 2026, and was reported to the public on June 9, 2026. The investment was valued in the range of $1,001 to $15,000.

Representative Cisneros Adds to Healthcare Holdings

This purchase by Representative Cisneros follows a pattern of activity for the congressman, who also reported buying shares of Sensata Technologies and STERIS plc earlier in May. Arcutis Biotherapeutics, which is based in Westlake Village, California, operates within the healthcare sector. This local connection is often a point of interest when members of Congress invest in companies headquartered in their home state. The transaction represents a relatively small entry into the biotechnology space for the representative's portfolio.

Arcutis Biotherapeutics Stock Performance

On Saturday, Arcutis Biotherapeutics shares were trading around $26.28. The stock has been moving slightly above its 50-day moving average of $25.91 and its 200-day moving average of $25.37. Over the past year, the company's shares have fluctuated between a low of $16.57 and a high of $31.77. With a market capitalization of approximately $3.26 billion, the company is currently profitable, showing a price-to-earnings (P/E) ratio of 118.0. Looking ahead, the forward P/E ratio sits at 19.1, suggesting expectations for higher earnings in the future.

Recent Earnings and Growth

Arcutis Biotherapeutics has shown strong momentum in its financial results. The company reported revenue of $463.98 million, which represents a growth rate of 59.3%. Arcutis maintains a net margin of 6.15% and a return on equity of 15.86%. Investors looking for more updates on the company's financial health can mark their calendars for October 27, 2026, when Arcutis is expected to release its next quarterly earnings report.

Insider Buying and Selling at Arcutis Biotherapeutics, Inc.

While Representative Cisneros was buying, some corporate insiders were trimming their holdings. On June 15, 2026, Sue-Jean Lin sold 4,946 shares at an average price of $24.38. Shortly after, on June 17, 2026, Howard Welgus sold 635 shares at $25.67 through a pre-planned trading schedule.

Analysts, however, have been raising their expectations. On October 15, 2026, Cantor Fitzgerald initiated coverage with an Overweight rating and a $48.00 price target. Earlier in August, Morgan Stanley, Guggenheim, and Needham all maintained positive ratings, with price targets ranging from $38.00 to $40.00. The current consensus among seven analysts is a buy, with an average price target of $37.00.

Developing Treatments for Skin Disease

Arcutis Biotherapeutics is a biopharmaceutical company that focuses on creating treatments for dermatological conditions. Their primary product is ZORYVE, a cream used to treat plaque psoriasis and atopic dermatitis. They are also working on other versions of the treatment for scalp and body psoriasis. As the company expands its commercial reach with these products, its performance remains a focal point for institutional investors and, now, members of Congress.

Monitoring Future Disclosures

Since this trade was disclosed through a periodic transaction report, it provides a window into the representative's activity shortly after it happened. Investors often watch these filings to see where lawmakers are putting their capital, though these trades are not necessarily a signal of future stock performance. Further updates on ownership will likely appear in future 13F filings from large institutional funds and additional STOCK Act disclosures from Capitol Hill.